Immune globulins
https://themeditary.com/dosage-information/kedrab-dosage-4689.html

Kedrab Dosage

Drug Detail:Kedrab (human) (Rabies immune globulin (human) (test))

Generic Name: Human Rabies Virus Immune Globulin 150[iU] in 1mL

Dosage Form: injection, solution

Drug Class: Immune globulins

Contents
Uses Warnings Before Taking Dosage Side effects Interactions

For wound infiltration and intramuscular use.

Dosage

Post-exposure prophylaxis consists of a single 20 IU/kg body weight dose of KEDRAB and a full course of rabies vaccine (See Table 1).

Table 1: Rabies Post-exposure Prophylaxis Schedule*

* Adapted from reference 1.

† These regimens are applicable for all age groups, including children.

ǂ Day 0 is the day the first dose of vaccine is administered. Refer to vaccine manufacturer's instructions or to the recommendations of the Advisory Committee on Immunization Practices (ACIP)1,2 for appropriate rabies vaccine formulations, schedules, and dosages.

§ Any person with a history of rabies vaccination and a documented history of antibody response to the prior vaccination.
Vaccination Status Intervention Regimen†
Not previously
vaccinated		 Wound Cleansing
  • Cleanse all wounds immediately and thoroughly with soap and water.
  • Irrigate the wounds with a viricidal agent such as a povidone-iodine solution, if available.
KEDRAB® 20 IU/kg body weight
  • Administer KEDRAB as soon as possible after exposure, preferably at the time of the first rabies vaccine dose. However, should a delay occur, administer KEDRAB at any time up to and including seven days after the first dose of rabies vaccine.
  • If there is a delay, initiate post-exposure prophylaxis at any time after exposure.
  • Infiltrate the area around and into the wound(s), if anatomically feasible, with the full dose of KEDRAB.
  • Inject the remainder, if any, intramuscularly at an anatomical site distant from the site of rabies vaccine administration.
  • Do not exceed the recommended dose of KEDRAB because this can partially suppress active production of rabies virus antibodies. [see Drug Interactions (7)]
  • Do not administer additional doses of KEDRAB, even if the antibody response to vaccination is delayed. (7)
  • Use separate syringes, needles, and anatomical injection sites for KEDRAB and for rabies vaccine.
Rabies Vaccine
  • Administer rabies vaccine on Day 0 and on subsequent vaccine administration daysǂ at an anatomical site that is distant from the KEDRAB administration site(s).
  • Complete a rabies vaccination series
Previously vaccinated§ Wound cleansing
  • Cleanse all wounds immediately and thoroughly with soap and water.
  • Irrigate the wounds with a viricidal agent such as povidone-iodine solution if available.
KEDRAB®
  • Do not administer KEDRAB. [see Warnings and Precautions (5.1)]
Rabies Vaccine
  • Administer rabies vaccine on Day 0.ǂ
  • Complete a rabies vaccination series for previously vaccinated persons.†
Other Considerations Tetanus prophylaxis and/or antibiotics
  • Provide treatment if medically indicated

Administration

Infiltrate as much of the KEDRAB dose as possible into and around any detectable bite wounds if infiltration at the bite site is feasible. Administer any remaining KEDRAB intramuscularly into anatomical site(s) distant from the site of the rabies vaccine.

  • When the bite site is unknown or indeterminate (undetectable) or if infiltration is difficult at the bite site (e.g., lips, fingers, knee), administer the full KEDRAB dose by the intramuscular route at a site distant from the site of rabies vaccination.
  • If a large intramuscular volume is required (>2 mL for children or >5 mL for adults), administer the total volume in divided doses at different sites.
  • Do not mix KEDRAB with the rabies vaccine or administer in the same syringe with the rabies vaccine.
  • Discard unused portion of the product in the vial.

​Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration. Do not use if either of these conditions exists, and contact Kedrion Biopharma Inc. at 1-855-353-7466. Do not discard the vial.

Share this Article
Latest News
Related Drugs